bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Authors: Stein Wilfred D. , Wilkerson Julia , Kim Sindy T. , Huang Xin , Motzer Robert J. , Fojo Antonio Tito , Bates Susan E.
Published: April 2023

PDF file - 48K
Supplementary Tables 1-4 from Recombinant Human Erythropoietin in Combination with Chemotherapy Increases Breast Cancer Metastasis in Preclinical Mouse Models
Authors: Hedley Benjamin D. , Chu Jenny E. , Ormond D. George , Beausoleil Michel S. , Boasie Alexandra , Allan Alison L. , Xenocostas Anargyros
Published: April 2023

PDF file - 119KB, Supplemental Table 1- Cell lines used. Supplemental Table 2 - PCR primers and cycling conditions. Supplemental Table 3 - Anti Human EPOR antibodies used. Supplemental Table 4 - In Vivo hemoglobin measurements.
Supplementary Figure 3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Authors: Stein Wilfred D. , Wilkerson Julia , Kim Sindy T. , Huang Xin , Motzer Robert J. , Fojo Antonio Tito , Bates Susan E.
Published: April 2023

PDF file - 128K
Supplementary Figure 1 from Recombinant Human Erythropoietin in Combination with Chemotherapy Increases Breast Cancer Metastasis in Preclinical Mouse Models
Authors: Hedley Benjamin D. , Chu Jenny E. , Ormond D. George , Beausoleil Michel S. , Boasie Alexandra , Allan Alison L. , Xenocostas Anargyros
Published: April 2023

PDF file - 145KB, EPOR and JAK2 amplification was normalized to GAPDH intensity for mBM, UT7/EPO, 3T3, H838, MDA-MB-435, MDA-MB-231, MDA-MB-468 and 4T1 samples, with (*) or without rHuEPO treatment and subjected to densitometric analysis.
Supplementary Table 1 from iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe
Authors: Jiang LiLi , Siu Michelle K.Y. , Wong Oscar G.W. , Tam Kai-Fai , Lu Xin , Lam Eric W-F. , Ngan Hextan Y.S. , Le Xiao-Feng , Wong Esther S.Y. , Monteiro Lara J. , Chan Hoi-Yan , Cheung Annie N.Y.
Published: April 2023

PDF file - 116K
Supplementary Data from Imaging Colon Cancer Response Following Treatment with AZD1152: A Preclinical Analysis of [18F]Fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]Fluorothymidine Imaging
Authors: Moroz Maxim A. , Kochetkov Tatiana , Cai Shangde , Wu Jiyuan , Shamis Mikhail , Nair Jayasree , de Stanchina Elisa , Serganova Inna , Schwartz Gary K. , Banerjee Debabrata , Bertino Joseph R. , Blasberg Ronald G.
Published: April 2023

Supplementary Figure S1; Supplementary Table S1.
Supplementary Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Authors: Jänne Pasi A. , Boss David S. , Camidge D. Ross , Britten Carolyn D. , Engelman Jeffrey A. , Garon Edward B. , Guo Feng , Wong Steven , Liang Jane , Letrent Stephen , Millham Robert , Taylor Ian , Eckhardt S. Gail , Schellens Jan H.M.
Published: April 2023

Supplementary Figures S1-S5; Supplementary Tables S1-S4.
Supplementary Figure 3 from VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Authors: Lu Hailing , Dietsch Gregory N. , Matthews Maura-Ann H. , Yang Yi , Ghanekar Smita , Inokuma Margaret , Suni Maria , Maino Vernon C. , Henderson Katherine E. , Howbert James Jeffry , Disis Mary L. , Hershberg Robert M.
Published: April 2023

PDF file - 88K
Supplementary Figure 2 from VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Authors: Lu Hailing , Dietsch Gregory N. , Matthews Maura-Ann H. , Yang Yi , Ghanekar Smita , Inokuma Margaret , Suni Maria , Maino Vernon C. , Henderson Katherine E. , Howbert James Jeffry , Disis Mary L. , Hershberg Robert M.
Published: April 2023

PDF file - 69K
Supplementary Table 8 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 60K
Supplementary Table 7 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 70K
Supplementary Table 2 from Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer
Authors: Kondo Shunsuke , Iwata Satoshi , Yamada Taketo , Inoue Yusuke , Ichihara Hiromi , Kichikawa Yoshiko , Katayose Tomoki , Souta-Kuribara Akiko , Yamazaki Hiroto , Hosono Osamu , Kawasaki Hiroshi , Tanaka Hirotoshi , Hayashi Yuichiro , Sakamoto Michiie , Kamiya Kazunori , Dang Nam H. , Morimoto Chikao
Published: April 2023

XLSX file, 15K, Clinical Characteristics and NEDD9 scoring of 60 NSCLC patients
Supplementary Figure 4 from Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer
Authors: Kondo Shunsuke , Iwata Satoshi , Yamada Taketo , Inoue Yusuke , Ichihara Hiromi , Kichikawa Yoshiko , Katayose Tomoki , Souta-Kuribara Akiko , Yamazaki Hiroto , Hosono Osamu , Kawasaki Hiroshi , Tanaka Hirotoshi , Hayashi Yuichiro , Sakamoto Michiie , Kamiya Kazunori , Dang Nam H. , Morimoto Chikao
Published: April 2023

PDF file - 78K, Survival curves in the various setting of cutoff value of NEDD9 positivity
Supplementary Figure Legends 1-7 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 82K
Supplementary Figure 6 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 564K
Supplementary Table 2 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
Authors: Agnelli Luca , Forcato Mattia , Ferrari Francesco , Tuana Giacomo , Todoerti Katia , Walker Brian A. , Morgan Gareth J. , Lombardi Luigia , Bicciato Silvio , Neri Antonino
Published: April 2023

XLS file - 608K
Supplementary Figure 1 from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

PDF file - 324K
Supplementary Figure Legends 1-3 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
Authors: Agnelli Luca , Forcato Mattia , Ferrari Francesco , Tuana Giacomo , Todoerti Katia , Walker Brian A. , Morgan Gareth J. , Lombardi Luigia , Bicciato Silvio , Neri Antonino
Published: April 2023

PDF file - 77K
Supplementary Figure 3 from The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma
Authors: Agnelli Luca , Forcato Mattia , Ferrari Francesco , Tuana Giacomo , Todoerti Katia , Walker Brian A. , Morgan Gareth J. , Lombardi Luigia , Bicciato Silvio , Neri Antonino
Published: April 2023

PDF file - 1.23MB
Supplementary Figure 1 from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Authors: Mross Klaus , Frost Annette , Steinbild Simone , Hedbom Susanne , Büchert Martin , Fasol Ulrike , Unger Clemens , Krätzschmar Jörn , Heinig Roland , Boix Oliver , Christensen Olaf
Published: April 2023

PDF file, 71KB, Best responses (maximum reduction in sum of longest diameter of target lesions from baseline) in individual patients.
Supplementary Table 1 from Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I
Authors: Sippel Trisha R. , White Jason , Nag Kamalika , Tsvankin Vadim , Klaassen Marci , Kleinschmidt-DeMasters B.K. , Waziri Allen
Published: April 2023

PDF file - 46K
Supplementary Tables 1-3 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 82K
Supplementary Figure 2 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Authors: Karapanagiotou Eleni M. , Roulstone Victoria , Twigger Katie , Ball Mercel , Tanay MaryAnne , Nutting Chris , Newbold Kate , Gore Martin E. , Larkin James , Syrigos Konstantinos N. , Coffey Matt , Thompson Brad , Mettinger Karl , Vile Richard G. , Pandha Hardev S. , Hall Geoff D. , Melcher Alan A. , Chester John , Harrington Kevin J.
Published: April 2023

PDF file - 43K
Supplementary Methods and Materials from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 144K
Supplementary Table 1 from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Authors: Hong David S. , Kurzrock Razelle , Supko Jeffrey G. , He Xiaoying , Naing Aung , Wheler Jennifer , Lawrence Donald , Eder Joseph Paul , Meyer Colin J. , Ferguson Deborah A. , Mier James , Konopleva Marina , Konoplev Sergej , Andreeff Michael , Kufe Donald , Lazarus Hillard , Shapiro Geoffrey I. , Dezube Bruce J.
Published: April 2023

PDF file, 63K, Changes in Serum Creatinine Following Treatment with Bardoxolone Methyl.
Supplementary Figure Legend from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Authors: Hong David S. , Kurzrock Razelle , Supko Jeffrey G. , He Xiaoying , Naing Aung , Wheler Jennifer , Lawrence Donald , Eder Joseph Paul , Meyer Colin J. , Ferguson Deborah A. , Mier James , Konopleva Marina , Konoplev Sergej , Andreeff Michael , Kufe Donald , Lazarus Hillard , Shapiro Geoffrey I. , Dezube Bruce J.
Published: April 2023

PDF file, 43K.
Supplementary Figure 1 from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Authors: Hong David S. , Kurzrock Razelle , Supko Jeffrey G. , He Xiaoying , Naing Aung , Wheler Jennifer , Lawrence Donald , Eder Joseph Paul , Meyer Colin J. , Ferguson Deborah A. , Mier James , Konopleva Marina , Konoplev Sergej , Andreeff Michael , Kufe Donald , Lazarus Hillard , Shapiro Geoffrey I. , Dezube Bruce J.
Published: April 2023

PDF file, 19K, Line graph representing the mean change in eGFR for nine patients that received bardoxolone methyl treatment for at least six cycles. Error bars represent the SEM.
Related Article from BAP1tism of a Tumor Suppressor
Authors: Woodman Scott E.
Published: April 2023

Related Article from BAP1tism of a Tumor Suppressor
Supplementary Data from KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
Authors: Tie Jeanne , Lipton Lara , Desai Jayesh , Gibbs Peter , Jorissen Robert N. , Christie Michael , Drummond Katharine J. , Thomson Benjamin N.J. , Usatoff Valery , Evans Peter M. , Pick Adrian W. , Knight Simon , Carne Peter W.G. , Berry Roger , Polglase Adrian , McMurrick Paul , Zhao Qi , Busam Dana , Strausberg Robert L. , Domingo Enric , Tomlinson Ian P.M. , Midgley Rachel , Kerr David , Sieber Oliver M.
Published: April 2023

Supplementary Tables S1-S4.
Supplementary Figure 2 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 1.8K, Percentage of sub-G1 phase apoptotic cells and apoptotic pathway induced by Ran silencing in different cell lines. (A) Cells were harvested 72 hours post-infection, fixed and stained with Propidium iodide. Significantly fewer Sub-G1 phase apoptotic cells were observed in the immortalized human embryonic kidney 293 (HEK 293) cell line compared to cancer cell lines from breast (MDA MB231), lung (A549), prostate (DU145), esophageal (EC109) and colon (HCT116 and DLD-1) upon Ran silencing (p < 0.01). (B) Western blots of apoptosis mediators in immortalized HEK293, breast (MDA MB231), lung (A549), prostate (DU145), esophageal (EC109) and colon (DLD-1 and HCT116) cancer cell lines at 72 hours post-infection with Scr or Ran shRNAs.
Supplementary Figure 10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 1.5MB, The importance of nucleocytoplasmic transportation and Mcl-1 expression in Ran silencing-induced apoptosis in A549 cells. Cells were grown in different conditions at 24 hours post-infection and were then harvested at 72 hours post-infection. Percentage of sub-G1 phase apoptotic cells are shown in A549 cells treated with (A) rapamycin and/or LMB, and (B) PI103 and/or LMB. Western blots of PARP, Mcl-1 and Ran, in A549 cells expressing various levels of Ran treated with (C) rapamycin and/or LMB, and (D) PI103 and/or LMB. Western blots of various transcription factors in cytoplasmic and nuclear fraction of scramble (Scr) and Ran knockdown (E) A549 cells, (F) A549 cells with or without rapamycin, (G) A549 cells with or without PD184352. (H) Quantitative PCR of Mcl-1 transcript in A549 cells infected with Scr and Ran shRNAs. (I) Western blots of Mcl-1, PARP and Ran at 72hr post-infection of Ran shRNAs in A549 cells grown in Hank's buffered salt solution (HBSS), serum-free and serum-supplemented conditions. (J) Quantification of Mcl-1 protein levels from figure (I). (K) Western blots of PARP, Mcl-1 and Bcl-2 in MDA MB231 cells upon Ran silencing in the presence of different inhibitors. (L) Quantification of Mcl-1 protein levels from figure.
Supplementary Figure 1 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Authors: Yuen Hiu-Fung , Chan Ka-Kui , Grills Claire , Murray James T. , Platt-Higgins Angela , Eldin Osama Sharaf , O'Byrne Ken , Janne Pasi , Fennell Dean A. , Johnston Patrick G. , Rudland Philip S. , El-Tanani Mohamed
Published: April 2023

PDF file - 1.9MB, Ran silencing induced apoptosis is concentration dependent. Effect of Ran silencing on apoptotic induction was tested using five different shRNAs (shRan1-5) targeting different regions of Ran compared to scramble shRNA (shScr) control in MDA MB231 breast cancer and A549 lung cancer cells. (A) mRNA and (B) protein levels of Ran, and (C) Flow cytometric analysis for DNA content, in MDA MB231 cells infected with different shRNAs targeting Ran. (D) Protein level and (E) Flow analysis for DNA content in A549 cells infected with different shRNAs targeting Ran. Note that the decrease in Ran mRNA level was associated with the decrease in Ran protein levels (r = 0.950, p < 0.01) in MDA MB231 cells infected with shRan1-5. In addition, the percentage of sub-G1 phase apoptotic cells induced by Ran silencing was significantly inversely associated with the levels of Ran in protein levels in MDA MB231 breast cancer cells (r = -0.880, p <0.05). Similar results were obtained in A549 cells.
Supplementary Table 1 from Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations
Authors: Eswaran Jeyanthy , Li Da-Qiang , Shah Anil , Kumar Rakesh
Published: April 2023

PDF file - 72K, Human cancers with altered expression of PAK1
Supplementary Table 2 from Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
Authors: Kitange Gaspar J. , Mladek Ann C. , Carlson Brett L. , Schroeder Mark A. , Pokorny Jenny L. , Cen Ling , Decker Paul A. , Wu Wenting , Lomberk Gwen A. , Gupta Shiv K. , Urrutia Raul A. , Sarkaria Jann N.
Published: April 2023

PDF file - 47K, MGMT promoter methylation by pyrosequencing: Parental vs TMZ resistant xenografts
Supplementary Figure 5 from Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Authors: Hudecek Michael , Lupo-Stanghellini Maria-Teresa , Kosasih Paula L. , Sommermeyer Daniel , Jensen Michael C. , Rader Christoph , Riddell Stanley R.
Published: April 2023

PDF File - 122K, Supplementary Figure 5: Expression of ROR1 and NKG2D ligands on epithelial cancer cell lines.
Supplementary Figure 4 from Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Authors: Hudecek Michael , Lupo-Stanghellini Maria-Teresa , Kosasih Paula L. , Sommermeyer Daniel , Jensen Michael C. , Rader Christoph , Riddell Stanley R.
Published: April 2023

PDF File - 169K, Supplementary Figure 4: The function of ROR1-CAR and CD19-CAR modified CD8+ T-cells against primary CLL is augmented by CAR-modified CD4+ helper T-cells.
Supplementary Figure 2 from Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
Authors: Kitange Gaspar J. , Mladek Ann C. , Carlson Brett L. , Schroeder Mark A. , Pokorny Jenny L. , Cen Ling , Decker Paul A. , Wu Wenting , Lomberk Gwen A. , Gupta Shiv K. , Urrutia Raul A. , Sarkaria Jann N.
Published: April 2023

PDF file - 99K, MSH6 mutation in TMZ resistant GBM22
Supplementary Figure 1 from Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
Authors: Kitange Gaspar J. , Mladek Ann C. , Carlson Brett L. , Schroeder Mark A. , Pokorny Jenny L. , Cen Ling , Decker Paul A. , Wu Wenting , Lomberk Gwen A. , Gupta Shiv K. , Urrutia Raul A. , Sarkaria Jann N.
Published: April 2023

PDF file - 100K, Kaplan-Meier survival plots: Parental vs TMZ resistant xenografts
Supplementary Figure Legend from miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways
Authors: Majid Shahana , Dar Altaf A. , Saini Sharanjot , Shahryari Varahram , Arora Sumit , Zaman Mohd Saif , Chang Inik , Yamamura Soichiro , Tanaka Yuichiro , Chiyomaru Takeshi , Deng Guoren , Dahiya Rajvir
Published: April 2023

PDF file - 62K
Supplementary Figure 6 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer
Authors: Deng Yong-Jian , Tang Na , Liu Chao , Zhang Jiang-Yu , An Sheng-Li , Peng Yin-Li , Ma Li-Li , Li Guang-Qiu , Jiang Qiang , Hu Chun-Ting , Wang Ya-Nan , Liang Yao-Ze , Bian Xiu-Wu , Fang Wei-Gang , Ding Yan-Qing
Published: April 2023

PDF file - 51K, Confirming the proteins associated with invasiveness and metastasis.
Supplementary Figure 1 from miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways
Authors: Majid Shahana , Dar Altaf A. , Saini Sharanjot , Shahryari Varahram , Arora Sumit , Zaman Mohd Saif , Chang Inik , Yamamura Soichiro , Tanaka Yuichiro , Chiyomaru Takeshi , Deng Guoren , Dahiya Rajvir
Published: April 2023

PDF file - 325K, Supplemental Figure 1: Downregulation of miR-34b expression, its potential diagnostic and prognostic significance and methylation status in PCa. A) Box plot representation of mir-34b expression in a cohort of unmatched tissue samples. B) Box plot representation of ISH results of tissue samples. (Ave- Average; T/N- Tumor/Normal). C) Chi-square test showing correlation of clinicopathological characteristics with miR-34b expression. D) CpG islands within the 1.0 kb region upstream of the miR-34b gene. Arrow indicates the start of the miR-34b gene. Locations for primers and probes are also shown on the miR-34b gene. F- Forward, R-Reverse, M/U Methylation and Unmethylation probes, CF1, CF2, CR1, CR2- ChiP Forward1-2, ChIP Reverse 1-2. E) Correlation of miR-34b expression with average percent methylation indicating cases with low miR-34b expression have higher methylation and vice versa.
Supplementary Figure 2 from CLIC4, ERp29, and Smac/DIABLO Derived from Metastatic Cancer Stem–like Cells Stratify Prognostic Risks of Colorectal Cancer
Authors: Deng Yong-Jian , Tang Na , Liu Chao , Zhang Jiang-Yu , An Sheng-Li , Peng Yin-Li , Ma Li-Li , Li Guang-Qiu , Jiang Qiang , Hu Chun-Ting , Wang Ya-Nan , Liang Yao-Ze , Bian Xiu-Wu , Fang Wei-Gang , Ding Yan-Qing
Published: April 2023

PDF file - 45K, Identifying cancer stem-like cells characteristics of tumor spheres.
Supplementary Table S2 from Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature
Authors: Sharma Anu , Bode Beata , Studer Gabriela , Moch Holger , Okoniewski Michal , Knuth Alexander , von Boehmer Lotta , van den Broek Maries
Published: April 2023

Supplementary Table S2 - PDF file 1109K, TaqMan Assays.
Supplementary Figure 5 from Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth
Authors: Ji Zhenyu , Kumar Raj , Taylor Michael , Rajadurai Anpuchchelvi , Marzuka-Alcalá Alexander , Chen Y. Erin , Njauw Ching-Ni Jenny , Flaherty Keith , Jönsson Göran , Tsao Hensin
Published: April 2023

PDF file, 86K, Overexpression of survivin leads to a decrease in percentage of FITC-annexin V positive cells.
Supplementary Figure S6 from Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature
Authors: Sharma Anu , Bode Beata , Studer Gabriela , Moch Holger , Okoniewski Michal , Knuth Alexander , von Boehmer Lotta , van den Broek Maries
Published: April 2023

Supplementary Figure S6 - PDF file 594K, Correlation between different immune response-related transcripts following radiotherapy in sarcoma patients: (A) Scatter dot plots demonstrating the significance of a bivariate correlation analysis (2-tailed). Each symbol represents an individual patient. Only correlations with a significant P value are represented in the figure. The solid line represents linear regression
Supplementary Figure S5 from Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature
Authors: Sharma Anu , Bode Beata , Studer Gabriela , Moch Holger , Okoniewski Michal , Knuth Alexander , von Boehmer Lotta , van den Broek Maries
Published: April 2023

Supplementary Figure S5 - PDF file 949K, Summary of radiotherapy-induced changes in human sarcoma at protein leve: IHC analysis of paired sarcoma samples before/after radiotherapy for (A) CD3 (B) CD4 (C) CD8 (D) MHC-I (E) CT7 and (F) NY-ESO-1. The horizontal bars on the bar graphs represent the median. Statistical analysis was performed for each target gene between the cohort before and after radiotherapy using the two-tailed bivariate analysis (Graphpad-Prism). The p-values of statistically different groups are displayed in the graph. The data for individual patients are shown in Fig. 2. ** Correlation is significant at the 0.01 level, *** Correlation is significant at the 0.001
Supplementary Figure 3 from Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth
Authors: Ji Zhenyu , Kumar Raj , Taylor Michael , Rajadurai Anpuchchelvi , Marzuka-Alcalá Alexander , Chen Y. Erin , Njauw Ching-Ni Jenny , Flaherty Keith , Jönsson Göran , Tsao Hensin
Published: April 2023

PDF file, 136K, Synergistic cytotoxicity between vemurafenib and Nt3. Green cells are live while dead cells are red in this assay.
Supplementary Figure 1 from Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth
Authors: Ji Zhenyu , Kumar Raj , Taylor Michael , Rajadurai Anpuchchelvi , Marzuka-Alcalá Alexander , Chen Y. Erin , Njauw Ching-Ni Jenny , Flaherty Keith , Jönsson Göran , Tsao Hensin
Published: April 2023

PDF file, 75K, Survival curves for A375 and A375(PLX-R) which have been induced into resistance.
Supplementary Table 2 from Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent Clinical Advances
Authors: Conte Mariarosaria , Altucci Lucia
Published: April 2023

PDF file, 66K, Main deregulation of acetylation in cancer. Renown modifications of acetylation in cancer are listed.
Supplementary Table 1 from Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent Clinical Advances
Authors: Conte Mariarosaria , Altucci Lucia
Published: April 2023

PDF file, 74K, Schematic representation of HAT alterations in cancer. The main HATs changes in cancer are indicated.
Data Supplement from Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
Authors: Blumenschein George R. , Saintigny Pierre , Liu Suyu , Kim Edward S. , Tsao Anne S. , Herbst Roy S. , Alden Christine , Lee J. Jack , Tang Ximing , Stewart David J. , Kies Merrill S. , Fossella Frank V. , Tran Hai T. , Mao L. , Hicks Marshall E. , Erasmus Jeremy , Gupta Sanjay , Girard Luc , Peyton Michael , Diao Lixia , Wang Jing , Davis Suzanne E. , Minna John D. , Wistuba Ignacio , Hong Waun K. , Heymach John V. , Lippman Scott M.
Published: April 2023

Supplementary Table 4. Eight-week disease control rates by EGFR mutation status stratified by ECOG performance status (4a) and by the number of prior lines of therapy before inclusion in the trial (4b).
Data Supplement from Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
Authors: Blumenschein George R. , Saintigny Pierre , Liu Suyu , Kim Edward S. , Tsao Anne S. , Herbst Roy S. , Alden Christine , Lee J. Jack , Tang Ximing , Stewart David J. , Kies Merrill S. , Fossella Frank V. , Tran Hai T. , Mao L. , Hicks Marshall E. , Erasmus Jeremy , Gupta Sanjay , Girard Luc , Peyton Michael , Diao Lixia , Wang Jing , Davis Suzanne E. , Minna John D. , Wistuba Ignacio , Hong Waun K. , Heymach John V. , Lippman Scott M.
Published: April 2023

Gene sets associated with sensitivity.
Supplementary Figure 3 from Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Authors: Wong Harvey , Vernillet Laurent , Peterson Amy , Ware Joseph A. , Lee Lillian , Martini Jean-Francois , Yu Peiwen , Li Congfen , Rosario Geoffrey Del , Choo Edna F. , Hoeflich Klaus P. , Shi Yongchang , Aftab Blake T. , Aoyama Ron , Lam Sanh Tan , Belvin Marcia , Prescott John
Published: April 2023

PDF file, 66KB, Plot of observed versus predicted GDC-0973 plasma concentrations following fitting of PK model (Figure 1A) to mean GDC-0973 plasma concentration-time data from patients in cohort 1.
Supplementary Figure 1 from Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Authors: Wong Harvey , Vernillet Laurent , Peterson Amy , Ware Joseph A. , Lee Lillian , Martini Jean-Francois , Yu Peiwen , Li Congfen , Rosario Geoffrey Del , Choo Edna F. , Hoeflich Klaus P. , Shi Yongchang , Aftab Blake T. , Aoyama Ron , Lam Sanh Tan , Belvin Marcia , Prescott John
Published: April 2023

PDF file, 57KB, Structure of GDC-0973.
Supplementary Methods from Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Authors: Voltan Rebecca , Secchiero Paola , Ruozi Barbara , Forni Flavio , Agostinis Chiara , Caruso Lorenzo , Vandelli Maria Angela , Zauli Giorgio
Published: April 2023

PDF file - 131K
Supplementary Figure 3 from Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Authors: Voltan Rebecca , Secchiero Paola , Ruozi Barbara , Forni Flavio , Agostinis Chiara , Caruso Lorenzo , Vandelli Maria Angela , Zauli Giorgio
Published: April 2023

PDF file - 70K, Supplementary Figure 3. Analysis of survival of JVM-2 xenograft mice.
Supplementary Figure 1 from Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Authors: Voltan Rebecca , Secchiero Paola , Ruozi Barbara , Forni Flavio , Agostinis Chiara , Caruso Lorenzo , Vandelli Maria Angela , Zauli Giorgio
Published: April 2023

PDF file - 307K, Supplementary Figure 1. Evidence of NP entry into cells.
Supplementary Tables 1 - 2 from Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Authors: Balasubramaniam Sucharitha , Comstock Clay E.S. , Ertel Adam , Jeong Kwang Won , Stallcup Michael R. , Addya Sankar , McCue Peter A. , Ostrander William F. , Augello Michael A. , Knudsen Karen E.
Published: April 2023

PDF file - 91K, Oligonucleotide Sequences and Kegg Pathway Summary.
Supplementary Figure 3 from Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition
Authors: Piao Yuji , Liang Ji , Holmes Lindsay , Henry Verlene , Sulman Erik , de Groot John F.
Published: April 2023

PDF file, 269K, Bevacizummab resistant cell lines are more invasive than their untreated controls.
Supplementary Figure 3 from Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Authors: Balasubramaniam Sucharitha , Comstock Clay E.S. , Ertel Adam , Jeong Kwang Won , Stallcup Michael R. , Addya Sankar , McCue Peter A. , Ostrander William F. , Augello Michael A. , Knudsen Karen E.
Published: April 2023

PDF file - 681K, BAF57 dependent modulation of integrin signaling.
Supplementary Table 1 from Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma
Authors: Bauer Daniel E. , Mitchell Chelsey M. , Strait Kelly M. , Lathan Christopher S. , Stelow Edward B. , Lüer Sonja C. , Muhammed Somala , Evans Andrew G. , Sholl Lynette M. , Rosai Juan , Giraldi Eugenia , Oakley Richard P. , Rodriguez-Galindo Carlos , London Wendy B. , Sallan Stephen E. , Bradner James E. , French Christopher A.
Published: April 2023

PDF file, 62K, Newly acquired unpublished clinical data for cases previously described by our group.
Supplementary Figure Legend from Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Authors: Boucher Kelly , Parquet Nancy , Widen Raymond , Shain Kenneth , Baz Rachid , Alsina Melissa , Koomen John , Anasetti Claudio , Dalton William , Perez Lia E.
Published: April 2023

PDF file - 65K
Supplementary Figures 1 - 10 from Improved Statistical Modeling of Tumor Growth and Treatment Effect in Preclinical Animal Studies with Highly Heterogeneous Responses In Vivo
Authors: Laajala Teemu D. , Corander Jukka , Saarinen Niina M. , Mäkelä Katja , Savolainen Saija , Suominen Mari I. , Alhoniemi Esa , Mäkelä Sari , Poutanen Matti , Aittokallio Tero
Published: April 2023

PDF file, 1943K, Data on real and simulated tumor growth experiments and power and precision analyses.
Supplementary Figure 3 from Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Authors: Boucher Kelly , Parquet Nancy , Widen Raymond , Shain Kenneth , Baz Rachid , Alsina Melissa , Koomen John , Anasetti Claudio , Dalton William , Perez Lia E.
Published: April 2023

PDF file - 87K, Contour plots describing sorting gating strategy and purity of bone marrow populations obtained
Supplementary Figure 1 from Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Authors: Boucher Kelly , Parquet Nancy , Widen Raymond , Shain Kenneth , Baz Rachid , Alsina Melissa , Koomen John , Anasetti Claudio , Dalton William , Perez Lia E.
Published: April 2023

PDF file - 90K, Contour plots describing our gating strategy to exclude contamination with monocytes
Supplementary Table 2 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
Authors: Walton Mike I. , Eve Paul D. , Hayes Angela , Valenti Melanie R. , De Haven Brandon Alexis K. , Box Gary , Hallsworth Albert , Smith Elizabeth L. , Boxall Kathy J. , Lainchbury Michael , Matthews Thomas P. , Jamin Yann , Robinson Simon P. , Aherne G. Wynne , Reader John C. , Chesler Louis , Raynaud Florence I. , Eccles Suzanne A. , Collins Ian , Garrett Michelle D.
Published: April 2023

PDF file, 118K, Supplementary Table 2 Summary of Effects of Irinotecan, Gemcitabine and CCT244747 alone or in combination on human tumor xenografts growth delay.
Supplementary Table 2 from The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma
Authors: Miyazaki Yasumasa , Kosaka Takeo , Mikami Shuji , Kikuchi Eiji , Tanaka Nobuyuki , Maeda Takahiro , Ishida Masaru , Miyajima Akira , Nakagawa Ken , Okada Yasunori , Sato Yasufumi , Oya Mototsugu
Published: April 2023

PDF file - 33K, Correlation of clinicopathological parameters and MVD or Vasohibin-1 expression in the 175 study patients: Patients with high grade tumors and �pT2 had significantly higher levels of VASH1 density
Supplementary Figure 5 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
Authors: Walton Mike I. , Eve Paul D. , Hayes Angela , Valenti Melanie R. , De Haven Brandon Alexis K. , Box Gary , Hallsworth Albert , Smith Elizabeth L. , Boxall Kathy J. , Lainchbury Michael , Matthews Thomas P. , Jamin Yann , Robinson Simon P. , Aherne G. Wynne , Reader John C. , Chesler Louis , Raynaud Florence I. , Eccles Suzanne A. , Collins Ian , Garrett Michelle D.
Published: April 2023

PDF file, 36K, Supplementary Figure 5. Effects of acute CCT244747 administration on non-tumor bearing GEMM mouse body weights. CCT244747 was administered at a dose of 150mg/kg p.o. x 7days and mouse body weights were measured daily. Results are mean�SD body weights for 5 mice. There was no apparent body weight loss, toxicity or morbidity following this treatment and hemizygous MYC-N tumor bearing GEMM mice were therefore treated with 100mg/kg CCT244747 p.o. x 7 days (see Figure 5).
Supplementary Figure 2 from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
Authors: Walton Mike I. , Eve Paul D. , Hayes Angela , Valenti Melanie R. , De Haven Brandon Alexis K. , Box Gary , Hallsworth Albert , Smith Elizabeth L. , Boxall Kathy J. , Lainchbury Michael , Matthews Thomas P. , Jamin Yann , Robinson Simon P. , Aherne G. Wynne , Reader John C. , Chesler Louis , Raynaud Florence I. , Eccles Suzanne A. , Collins Ian , Garrett Michelle D.
Published: April 2023

PDF file, 92K, Supplementary Figure 2. A constrained, scaffold docking model of CCT244747 in the ATP pocket of human CHK1 realized using the SAR-020106 X-ray crystal structure (PDB 2ym8).
Supplementary Figure Legend from Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Authors: Arcila Maria E. , Chaft Jamie E. , Nafa Khedoudja , Roy-Chowdhuri Sinchita , Lau Christopher , Zaidinski Michael , Paik Paul K. , Zakowski Maureen F. , Kris Mark G. , Ladanyi Marc
Published: April 2023

PDF file, 56K.
Supplementary Figure 1 from Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Authors: Arcila Maria E. , Chaft Jamie E. , Nafa Khedoudja , Roy-Chowdhuri Sinchita , Lau Christopher , Zaidinski Michael , Paik Paul K. , Zakowski Maureen F. , Kris Mark G. , Ladanyi Marc
Published: April 2023

PDF file, 56K, Flow chart of patients screened for mutations under the clinical and extended panels.
Supplementary Materials and Methods and Tables 1-5 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
Authors: Smith Christopher G. , Fisher David , Claes Bart , Maughan Timothy S. , Idziaszczyk Shelley , Peuteman Gilian , Harris Rebecca , James Michelle D. , Meade Angela , Jasani Bharat , Adams Richard A. , Kenny Sarah , Kaplan Richard , Lambrechts Diether , Cheadle Jeremy P.
Published: April 2023

PDF - 108K, Materials and Methods. Supplementary Table 1 - Primers used in Sequenom analysis of KRAS, BRAF, NRAS and PIK3CA. Supplementary Table 2 - The sensitivity of Pyrosequencing and Sequenom to detect somatic mutations in KRAS, BRAF, NRAS and PIK3CA. Mutant alleles that could, or could not, be detected indicated by Y and X, respectively. Supplementary Table 3 � Correlations between the site of the metastases and somatic mutation status (by individual mutations and for patients with a single organ metastatic site).Supplementary Table 4 � Correlations between the site of the metastases and somatic mutation status (in any patients with the metastatic site). Supplementary Table 5 � Correlations between the site of the metastases and somatic mutation status (in any patients with, or without, the metastatic site).
Supplementary Figure Legends from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab
Authors: Smith Christopher G. , Fisher David , Claes Bart , Maughan Timothy S. , Idziaszczyk Shelley , Peuteman Gilian , Harris Rebecca , James Michelle D. , Meade Angela , Jasani Bharat , Adams Richard A. , Kenny Sarah , Kaplan Richard , Lambrechts Diether , Cheadle Jeremy P.
Published: April 2023

PDF - 63K
Supplementary Figure Legend from EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival
Authors: Smits Michiel , van Rijn Sjoerd , Hulleman Esther , Biesmans Dennis , van Vuurden Dannis G. , Kool Marcel , Haberler Christine , Aronica Eleonora , Vandertop W. Peter , Noske David P. , Würdinger Thomas
Published: April 2023

PDF file, 67KB.
Supplementary Figure 3 from EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival
Authors: Smits Michiel , van Rijn Sjoerd , Hulleman Esther , Biesmans Dennis , van Vuurden Dannis G. , Kool Marcel , Haberler Christine , Aronica Eleonora , Vandertop W. Peter , Noske David P. , Würdinger Thomas
Published: April 2023

PDF file, 63KB, (A) Expression levels of DAB2IP mRNA compared to EZH2 mRNA levels in individual patients show a significant negative correlation. (B) Protein expression analysis of DAB2IP and EZH2 in various medulloblastoma cells and non-neoplastic brain.
Supplementary Table 1 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Authors: Troiani Teresa , Martinelli Erika , Napolitano Stefania , Vitagliano Donata , Ciuffreda Loreta Pia , Costantino Sara , Morgillo Floriana , Capasso Anna , Sforza Vincenzo , Nappi Anna , De Palma Raffaele , D'Aiuto Elena , Berrino Liberato , Bianco Roberto , Ciardiello Fortunato
Published: April 2023

PDF file 184K, genes up regulated in GEO-CR versus GEO
Supplementary Figure 2 from Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Authors: Troiani Teresa , Martinelli Erika , Napolitano Stefania , Vitagliano Donata , Ciuffreda Loreta Pia , Costantino Sara , Morgillo Floriana , Capasso Anna , Sforza Vincenzo , Nappi Anna , De Palma Raffaele , D'Aiuto Elena , Berrino Liberato , Bianco Roberto , Ciardiello Fortunato
Published: April 2023

PDF file 1516K, Inhibition of MET expression restores cetuximab sensitivity in SW48-CR cells
Supplementary Table 4 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Authors: Kemp Clinton D. , Rao Mahadev , Xi Sichuan , Inchauste Suzanne , Mani Haresh , Fetsch Patricia , Filie Armando , Zhang Mary , Hong Julie A. , Walker Robert L. , Zhu Yuelin J. , Ripley R. Taylor , Mathur Aarti , Liu Fang , Yang Maocheng , Meltzer Paul A. , Marquez Victor E. , De Rienzo Assunta , Bueno Raphael , Schrump David S.
Published: April 2023

PDF file - 63K, Genes Simultaneously Modulated by DZNep in MES1 and H28.
Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Authors: Smith Neil R. , Baker Dawn , Farren Matthew , Pommier Aurelien , Swann Ruth , Wang Xin , Mistry Sunita , McDaid Karen , Kendrew Jane , Womack Chris , Wedge Stephen R. , Barry Simon T.
Published: April 2023

PDF file - 211K, Additional biomarker responses to DC101 in Calu-3 xenograft model.
Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Authors: Smith Neil R. , Baker Dawn , Farren Matthew , Pommier Aurelien , Swann Ruth , Wang Xin , Mistry Sunita , McDaid Karen , Kendrew Jane , Womack Chris , Wedge Stephen R. , Barry Simon T.
Published: April 2023

PDF file - 2029K, Examples of tumour types classified as predominantly tumour vessel or stromal vessel phenotypes from TMA cores.
Supplementary Table 4 from Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness
Authors: Huang Cheng , Ding Guangyu , Gu Chengyu , Zhou Jian , Kuang Ming , Ji Yuan , He Yifeng , Kondo Tadashi , Fan Jia
Published: April 2023

PDF file - 129K, Multivariate analyses of factors associated with survival and recurrence in cohort 2
Supplementary Table 3 from Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness
Authors: Huang Cheng , Ding Guangyu , Gu Chengyu , Zhou Jian , Kuang Ming , Ji Yuan , He Yifeng , Kondo Tadashi , Fan Jia
Published: April 2023

PDF file - 130K, Univariate analyses of factors associated with survival and recurrence in cohort 2
Supplementary Table 1 from Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness
Authors: Huang Cheng , Ding Guangyu , Gu Chengyu , Zhou Jian , Kuang Ming , Ji Yuan , He Yifeng , Kondo Tadashi , Fan Jia
Published: April 2023

PDF file - 66K, Clinical characteristics of the 19 HCC patients used in cohort 1
Supplementary Figure 1 from Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness
Authors: Huang Cheng , Ding Guangyu , Gu Chengyu , Zhou Jian , Kuang Ming , Ji Yuan , He Yifeng , Kondo Tadashi , Fan Jia
Published: April 2023

PDF file - 73K, Supplemental Figure S1: The relationship of SBP1 Expression level and Prognosis. The expression levels of SBP1 in 323 HCC tissues were divided by a 4-point scale (0 - +++) system based on the number of positive cells and the intensity of staining. Kapl
Supplementary Methods from Ontogeny and Sorafenib Metabolism
Authors: Zimmerman Eric I. , Roberts Justin L. , Li Lie , Finkelstein David , Gibson Alice , Chaudhry Amarjit S. , Schuetz Erin G. , Rubnitz Jeffrey E. , Inaba Hiroto , Baker Sharyn D.
Published: April 2023

PDF file, 104K.
Supplementary Figure 7 from Ontogeny and Sorafenib Metabolism
Authors: Zimmerman Eric I. , Roberts Justin L. , Li Lie , Finkelstein David , Gibson Alice , Chaudhry Amarjit S. , Schuetz Erin G. , Rubnitz Jeffrey E. , Inaba Hiroto , Baker Sharyn D.
Published: April 2023

PDF file, 62K, Incurred sample reanalysis for sorafenib and sorafenib N-oxide.
Supplementary Tables 1 - 3 from Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Authors: Malouf Gabriel G. , Monzon Federico A. , Couturier Jérôme , Molinié Vincent , Escudier Bernard , Camparo Philippe , Su Xiaoping , Yao Hui , Tamboli Pheroze , Lopez-Terrada Dolores , Picken Maria , Garcia Marileila , Multani Asha S. , Pathak Sen , Wood Christopher G. , Tannir Nizar M.
Published: April 2023

PDF file - 86K, Supplementary Table 1. Clinicopathologic characteristics of patients with confirmed Translocation RCC Supplementary Table 2: Clinicopathological features of TFE3 overexpressing renal cell carcinoma with no TFE3 translocation identified. Supplementary Table 3: List of upstream regulators predicted to be activated or inhibited in two cases of translocation renal cell carcinoma with concomitant 17q gain and 17p loss as compared to two cases with balanced karyotype.
Supplementary Figure 6 from Ontogeny and Sorafenib Metabolism
Authors: Zimmerman Eric I. , Roberts Justin L. , Li Lie , Finkelstein David , Gibson Alice , Chaudhry Amarjit S. , Schuetz Erin G. , Rubnitz Jeffrey E. , Inaba Hiroto , Baker Sharyn D.
Published: April 2023

PDF file, 76K, Identification of sorafenib glucuronide by high resolution mass spectrometry.
Supplementary Figure 3 from Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Authors: Malouf Gabriel G. , Monzon Federico A. , Couturier Jérôme , Molinié Vincent , Escudier Bernard , Camparo Philippe , Su Xiaoping , Yao Hui , Tamboli Pheroze , Lopez-Terrada Dolores , Picken Maria , Garcia Marileila , Multani Asha S. , Pathak Sen , Wood Christopher G. , Tannir Nizar M.
Published: April 2023

PDF file - 130K, Supplementary Figure 3. A) Gene Set enrichment Analysis (GSEA) showing enrichment of mitosis pathways in cases with 17q gain. B, Ingenuity Pathway Analysis of genes expressed differently between samples with partial 17q gain and without it showing activation of ICOS-ICOSL signaling in T helper cells and activation of the CTLA4 signaling pathway.
Supplementary Figure 3 from Ontogeny and Sorafenib Metabolism
Authors: Zimmerman Eric I. , Roberts Justin L. , Li Lie , Finkelstein David , Gibson Alice , Chaudhry Amarjit S. , Schuetz Erin G. , Rubnitz Jeffrey E. , Inaba Hiroto , Baker Sharyn D.
Published: April 2023

PDF file, 93K, Inhibition of CYP3A4-mediated sorafenib metabolism by azole compounds.
Supplementary Figure 1 from Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Authors: Malouf Gabriel G. , Monzon Federico A. , Couturier Jérôme , Molinié Vincent , Escudier Bernard , Camparo Philippe , Su Xiaoping , Yao Hui , Tamboli Pheroze , Lopez-Terrada Dolores , Picken Maria , Garcia Marileila , Multani Asha S. , Pathak Sen , Wood Christopher G. , Tannir Nizar M.
Published: April 2023

PDF file - 135K, Supplementary Figure 1. Flow chart for patient selection and different tested performed.
Supplementary Table 2 from Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Authors: Dunbier Anita K. , Ghazoui Zara , Anderson Helen , Salter Janine , Nerurkar Ashutosh , Osin Peter , A'hern Roger , Miller William R. , Smith Ian E. , Dowsett Mitch
Published: April 2023

XLSX file - 250K, Excel file of differentially expressed and correlated genes.